A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
BACKGROUND: There is little data on how semaglutide affects basal versus bolus insulin and dosing parameters in adults with type 1 diabetes on insulin pump therapy. METHODS: This is a post-hoc analysis of a double-blinded, randomised, crossover trial…
OBJECTIVE: Eating disorders (ED) and psychological distress are highly prevalent in individuals with Class 3 obesity (BMI ≥ 40 kg/m). With the increasing use of glucagon-like peptide-1 receptor agonists (GLP1-RA), concerns have emerged about the pote…
BACKGROUND AND AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a progressive condition characterized by excess hepatic fat accumulation in the absence of significant hepatocellular injury. Its more severe form, metabolic dys…
The development of glucagon-like peptide 1 (GLP1) receptor agonists, including semaglutide and tirzepatide, has transformed the clinical management of overweight and obesity. However, substantial inter-person variability exists in both weight loss ef…
Semaglutide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA), is widely used in the treatment of patients with type 2 diabetes mellitus and obesity. A sensitive and reliable quantification method is essential for bioanalysis of semag…
Targeted screening for steatotic liver disease (SLD) is cost-effective and encourages lifestyle changes.The European Association for the Study of the Liver (EASL) recommends screening adults at risk of SLD to enable timely diagnosis and prevention, e…
OBJECTIVES: To explore the association of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on heart rate (HR) in overweight or obese patients without diabetes. METHODS: A comprehensive search of the PubMed, Web of Science, Embase, and Cochrane Li…
This rapid review aimed to evaluate the effects of GLP-1 RAs on eating behaviors and eating disorder risk. Databases were searched to January 2025 to identify studies evaluating GLP-1 RA treatment for adolescents or adults with obesity or Type 2 diab…
Obesity is a chronic, multifactorial condition strongly associated with increased cardiovascular and metabolic risk, as well as the development of systemic complications. Recent evidence from randomized controlled trials-including SELECT, STEP-HFpEF,…
The global prevalence of diabetes mellitus (DM) and heart failure (HF) is rapidly increasing. Hyperglycemia, insulin resistance and hyperglycemia-induced oxidative stress in people with DM are the key etiological factors of HF. The factors disrupt sy…
Autism spectrum disorder (ASD) is a multifaceted neurodevelopmental condition characterized by deficits in social communication and the presence of repetitive behaviors. The significance of the gut-brain axis in the pathogenesis of ASD often points t…
BACKGROUND: Effective weight management and glycemic control are both important in people with type 2 diabetes (T2D) and obesity. Despite the proven benefits of GLP-1 receptor agonists, there is a persistent need for more effective weight management…
AIMS: Real-world medication use varies across clinical trial and healthcare settings; therefore, we evaluated GLP-1 receptor agonist (GLP-1RA) persistence and dose titration among adults with type 2 diabetes in UK primary care, stratified by agent, o…
Glucagon-like peptide-1 (GLP-1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with the gut microbiome remain an emerging frontier in pharmacological and metabolic research. Mo…
BACKGROUND: Despite the documented clinical efficacy of weight loss medications, few large-scale mixed methods studies have captured the experiences of individuals taking these medications. OBJECTIVE: This study aims to examine dominant themes and pu…
OBJECTIVE: We examined whether the addition of GLP-1RA to progestin therapy reduced the risk of hysterectomy in patients with endometrial intraepithelial neoplasia (EIN) and endometrial cancer (EC) in the U.S. managed with fertility-sparing managemen…
Sublingual delivery of peptide therapeutics is hindered by mucosal barriers and poor bioavailability. This study aimed to evaluate and optimize sublingual administration of TE-8105, a long-acting dual fatty acid-conjugated GLP-1 receptor agonist that…
The NLRP3 inflammasome is a key innate immune sensor that orchestrates inflammatory responses to diverse stress signals, including metabolic danger cues. Dysregulated NLRP3 activation has been implicated in chronic diseases such as type 2 diabetes, a…
BACKGROUND/OBJECTIVE: Recent observational studies report conflicting evidence on whether semaglutide use is associated with non-arteritic anterior ischemic optic neuropathy (NAION). This systematic review synthesizes available evidence and criticall…